Li-Ning, Asics Sign Western Stars as Nike, Adidas Lose Signature Athlete Grip

Li-Ning paid Dwyane Wade an estimated $10 million annually starting in 2012. Asics signed Emma Raducanu in 2022, weeks after her US Open win, for a reported $4.5 million over three years. Uniqlo locked Roger Federer into a $300 million ten-year deal in 2018, no performance bonuses required. The pattern is consistent: Asian brands write checks North American athletes cannot ignore, and the majors do not always match.

The shift matters because signature athlete deals historically locked in category dominance. Nike paid Michael Jordan 3% of Air Jordan revenue; Adidas gave James Harden 15% of Harden Volume sales. Those structures created switching costs. Li-Ning and Asics write flat-fee contracts with lower royalty exposure, which compresses their risk but also limits athlete upside. Stephen Curry's Under Armour deal included equity; his Li-Ning predecessor Jimmy Butler took guaranteed money. The incentive architecture is different, and it shows in retention rates. Raducanu's Asics deal expires in 2025. Her agent is already fielding calls.

The category pressure is clearest in running and tennis, where Asics and On Running are taking shelf space. Asics reported $4.2 billion in revenue for fiscal 2023, up 12% year-over-year, with North America growing faster than Japan for the first time since 2019. On Running, backed by Roger Federer's equity stake, hit $1.8 billion in 2023 revenue, a 47% climb. Nike's running category grew 6% in the same period. Adidas declined 1%. The margin gap is tightening, and retailers notice. Foot Locker expanded its Asics SKU count by 18% in Q4 2024. Dick's Sporting Goods added Li-Ning to 120 stores in February. Those placements came at someone's expense.

Sponsor CMOs are watching player equity structures. Curry's Under Armour stake vested at roughly $75 million before the stock collapse; his current deal includes board influence but no additional equity. Li-Ning offered him a straight endorsement fee and creative control over the "Way of Wade" China sub-brand. The trade-off: liquidity now, no long-term appreciation. Family offices sizing apparel plays are asking whether athlete equity creates defensibility or just deferred comp risk. The answer depends on whether the brand can scale without the athlete. Jordan Brand did. Yeezy did not.

Nike's response has been vertical: more NIL deals, tighter college pipelines, earlier locks on high school phenoms. Adidas is cutting SKU count and reallocating marketing spend toward soccer, where it still owns 37% global share versus Nike's 34%. Neither is panicking, but both are adjusting. When a brand that paid $1 billion annually in athlete endorsements in 2022 starts shifting toward performance tech marketing instead of signature shoes, the message is clear. The athlete premium is compressing.

Watch Raducanu's 2025 renewal window. If Asics does not extend, Nike will bid, but so will New Balance, which just opened a $500 million Boston expansion and needs a women's tennis anchor. Watch Li-Ning's NBA roster adds; the brand signed 12 players in 2023, mostly second-unit guys, but it is hunting a top-15 scorer. Watch On Running's IPO lockup expiration in June 2025, when Federer's stake becomes partially liquid. If he sells more than 10%, the brand's athlete-equity pitch loses credibility.

The Western athlete is not a trophy signing anymore. He is a distribution wedge, and the Asians are learning to sharpen it without paying Jordan-level royalties.